Johnson & Johnson's Tremfya Shows Efficacy In Late-Stage Psoriatic Arthritis Study
Johnson & Johnson's Phase 3b APEX study shows Tremfya reduces symptoms and structural damage in psoriatic arthritis patients ...
J&J highlights Tremfya’s efficacy against psoriatic arthritis in Phase 3 trial win
Johnson & Johnson (JNJ) reports a Phase 3 success for its anti-inflammatory drug Tremfya in treating psoriatic arthritis.
Barchart on MSN14h
Earnings Preview: What to Expect From Johnson & Johnson's Report
Headquartered in New Brunswick, New Jersey, Johnson & Johnson (JNJ) researches and develops, manufactures, and sells various ...
J&J's experimental antiviral drug shows promise against COVID-19 and emerging coronaviruses
This development comes at a time when pharmaceutical firms are discontinuing discovery efforts in next-generation COVID-19 ...
Guggenheim Reiterates Neutral Rating for Johnson & Johnson (NYSE:JNJ)
Johnson & Johnson (NYSE:JNJ – Get Free Report)‘s stock had its “neutral” rating reaffirmed by analysts at Guggenheim in a ...
Johnson & Johnson’s (JNJ) “Outperform” Rating Reiterated at Royal Bank of Canada
Johnson & Johnson (NYSE:JNJ – Get Free Report)‘s stock had its “outperform” rating reaffirmed by Royal Bank of Canada in a research note issued on Wednesday,Benzinga reports. They currently have a ...